Cardiovascular Safety of Testosterone-Replacement Therapy

In a randomized trial involving men with hypogonadism and preexisting or a risk of cardiovascular disease, testosterone therapy was noninferior to placebo with respect to major adverse cardiac events.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 389; no. 2; pp. 107 - 117
Main Authors: Lincoff, A. Michael, Bhasin, Shalender, Flevaris, Panagiotis, Mitchell, Lisa M., Basaria, Shehzad, Boden, William E., Cunningham, Glenn R., Granger, Christopher B., Khera, Mohit, Thompson, Ian M., Wang, Qiuqing, Wolski, Kathy, Davey, Deborah, Kalahasti, Vidyasagar, Khan, Nader, Miller, Michael G., Snabes, Michael C., Chan, Anna, Dubcenco, Elena, Li, Xue, Yi, Tingting, Huang, Bidan, Pencina, Karol M., Travison, Thomas G., Nissen, Steven E.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 13-07-2023
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a randomized trial involving men with hypogonadism and preexisting or a risk of cardiovascular disease, testosterone therapy was noninferior to placebo with respect to major adverse cardiac events.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2215025